Semaglutide Shows Promise for Fatty Liver Disease
Semaglutide is effective in the treatment of NAFLD while maintaining a well-tolerated safety profile
Abstract Background: Nonalcoholic fatty liver disease (NAFLD) is commonly observed in patients with type 2 diabetes (T2D)
11, I 2 =57%) and steatosis (MD -4
To date, there are no approved pharmacotherapies for NAFLD or non-alcoholic steatohepatitis (NASH)
(2019) conducted a post hoc analysis using data from two randomized, double-blind trials regarding the
Semaglutide is an especially interesting agent with favorable metabolic actions in patients sharing T2DM and MAFLD (but also sole MAFLD) phenotype, available in
The weight loss following Semaglutide treatment, a GLP-1 receptor agonist, might be responsible for some effects observed on the nonalcoholic fatty liver disease of
Introduction: Childhood obesity is a global concern and has both nutritional and genetic causative factors
Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes
This includes hepatic steatosis, where 5% or more hepatocytes have macrovesicular steatosis in the absence of other
Characterized by an excessive accumulation of intra-hepatocyte lipids, it can be complicated by the development of inflammation and
89, 1
2-mg group, and in 83% in To clarify this point, we have added at the end of the “Introduction” section that we evaluated the “effectiveness of diabetes therapeutic dosages of subcutaneous Semaglutide on fatty liver disease and surrogate markers of NAFLD in patients with T2D, treated once-weekly for 52 weeks”, precisely because it is a real-life study
At 6 months after initiation of semaglutide, liver-related parameters (AST, ALT, γ-GTP, LDH) were significantly improved
Key Words: Non-alcoholic fatty liver disease, Fatty liver, Metabolic-associated fatty liver, Semaglutide
1 Accumulating data are emerging regarding the beneficial effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with NAFLD
Semaglutide, pioglitazone, and dapagliflozin were superior to placebo in decreasing the AST level
et al
It belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists
It is currently the most common chronic liver disease in the world and is estimated to affect as much as a
NAFLD describes a group of conditions that occur when fat builds up in the liver in people who drink Treatment options for nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), two conditions which coexist, are limited though weight loss is an important strategy to improve outcomes alcoholic fatty liver disease 19 of 4 or higher, with a subscore of 1 or higher for each subcomponent (steatosis, hepatocyte ballooning, and lobular daily semaglutide was initiated at a dose Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD), characterized with hepatocellular steatosis, ballooning, lobular inflammation, fibrotic Non-alcoholic fatty liver disease (NAFLD) is an important common comorbidity in individuals with type 2 diabetes (T2DM)